These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 27507298)
1. Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice. Giocanti-Auregan A; Tadayoni R; Grenet T; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Quentel G; Cohen SY BMC Ophthalmol; 2016 Aug; 16():142. PubMed ID: 27507298 [TBL] [Abstract][Full Text] [Related]
2. Real world evidence of use of anti-VEGF therapy in Denmark. Vorum H; Olesen TK; Zinck J; Størling Hedegaard M Curr Med Res Opin; 2016 Dec; 32(12):1943-1950. PubMed ID: 27494692 [TBL] [Abstract][Full Text] [Related]
4. Nurse-administered intravitreal injections of anti-VEGF: study protocol for noninferiority randomized controlled trial of safety, cost and patient satisfaction. Austeng D; Morken TS; Bolme S; Follestad T; Halsteinli V BMC Ophthalmol; 2016 Oct; 16(1):169. PubMed ID: 27716253 [TBL] [Abstract][Full Text] [Related]
5. Treatment patterns for retinal diseases in patients newly-treated with anti-VEGF agents: A retrospective analysis of claims data from the Japan Medical Data Center database. Kawasaki R; Bauer M; Bezlyak V; Ogura Y Jpn J Ophthalmol; 2021 Mar; 65(2):215-226. PubMed ID: 33420855 [TBL] [Abstract][Full Text] [Related]
6. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Chan WM; Lai TY; Chan KP; Li H; Liu DT; Lam DS; Pang CP Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A Retina; 2007; 27(4):432-8. PubMed ID: 17420694 [TBL] [Abstract][Full Text] [Related]
9. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630 [TBL] [Abstract][Full Text] [Related]
10. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278 [TBL] [Abstract][Full Text] [Related]
12. Predictability of Recalcitrance in Neovascular Age-Related Macular Degeneration With Indocyanine Green Angiography. Rush RB; Rush SW Asia Pac J Ophthalmol (Phila); 2015; 4(4):187-90. PubMed ID: 26147016 [TBL] [Abstract][Full Text] [Related]
13. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]. Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687 [TBL] [Abstract][Full Text] [Related]
14. National survey of the ophthalmic use of anti-vascular endothelial growth factor drugs in Israel. Waisbourd M; Goldstein M; Loewenstein A Isr Med Assoc J; 2011 Mar; 13(3):141-6. PubMed ID: 21608333 [TBL] [Abstract][Full Text] [Related]
15. Recovery of plasma vascular endothelial growth factor concentrations during aflibercept loading phase and after the transition to bimonthly treatment for neovascular age-related macular degeneration. Roald AB; Aass HC; Moe MC Br J Ophthalmol; 2015 Dec; 99(12):1610-3. PubMed ID: 25966740 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program. Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658 [TBL] [Abstract][Full Text] [Related]
17. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ikuno Y; Ohno-Matsui K; Wong TY; Korobelnik JF; Vitti R; Li T; Stemper B; Asmus F; Zeitz O; Ishibashi T; Ophthalmology; 2015 Jun; 122(6):1220-7. PubMed ID: 25745875 [TBL] [Abstract][Full Text] [Related]
18. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506 [TBL] [Abstract][Full Text] [Related]
19. [Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study]. Baeteman C; Hoffart L; Galland F; Ridings B; Conrath J J Fr Ophtalmol; 2009 May; 32(5):309-13. PubMed ID: 19769866 [TBL] [Abstract][Full Text] [Related]
20. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization. Ahn SJ; Park KH; Woo SJ Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]